GURUFOCUS.COM » STOCK LIST » USA » NAS » Grifols SA (NAS:GRFS) » Definitions » EV-to-EBITDA
Switch to:

Grifols EV-to-EBITDA

: 52.81 (As of Today)
View and export this data going back to 2011. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grifols's enterprise value is $15,257 Mil. Grifols's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $289 Mil. Therefore, Grifols's EV-to-EBITDA for today is 52.81.

The historical rank and industry rank for Grifols's EV-to-EBITDA or its related term are showing as below:

GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.08   Med: 12.32   Max: 54.16
Current: 53.93

During the past 13 years, the highest EV-to-EBITDA of Grifols was 54.16. The lowest was 7.08. And the median was 12.32.

GRFS's EV-to-EBITDA is ranked worse than
91.96% of 709 companies
in the Drug Manufacturers industry
Industry Median: 13.00 vs GRFS: 53.93

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2022-08-15), Grifols's stock price is $8.90. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $0.137. Therefore, Grifols's PE Ratio for today is 64.96.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Grifols EV-to-EBITDA Historical Data

The historical data trend for Grifols's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.39 7.45 13.89 12.72 16.48

Grifols Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.72 18.18 12.96 16.48 85.36

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Grifols EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grifols's EV-to-EBITDA falls into.



Grifols EV-to-EBITDA Calculation

Grifols's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15256.784/288.89852008457
=52.81

Grifols's current Enterprise Value is $15,257 Mil.
Grifols's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $289 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (NAS:GRFS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Grifols's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.90/0.137
=64.96

Grifols's share price for today is $8.90.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.137.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Grifols EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grifols's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Grifols logo
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.

Grifols Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)